News Agency
Men's Weekly

First Patient Dosed in Clinical Trial of YOLT-101 for the Treatment of FH

  • Written by PR Newswire

SHANGHAI, April 2, 2024 /PRNewswire/ -- YolTech Therapeutics announced that the first patient has been dosed with YOLT-101, the company's in vivo genome editing candidate being developed as a single dose, potentially curative therapy for Familial Hypercholesterolemia(FH), marking the commencement of an Investigator-Initiated Trial (IIT).

Familial...

Read more: First Patient Dosed in Clinical Trial of YOLT-101 for the Treatment of FH

Managing Business Risk Through Content Governance in Headless CMS

As businesses scale their digital presence, content becomes a critical asset that directly impacts reputation, compliance, and operational efficiency. However, without proper governance, content can quickly become a source of risk. Inaccurate information, inconsistent messaging, or non-compliant content can lead... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion